Clinical Trials Logo

Pericarditis clinical trials

View clinical trials related to Pericarditis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06113692 Active, not recruiting - Clinical trials for Myocarditis, Pericarditis

A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine

Start date: March 31, 2023
Phase:
Study type: Observational

The main goal of this study is to describe the clinical course, outcomes and risk factors for myocarditis and pericarditis associated with Moderna vaccination targeting SARS-CoV-2.

NCT ID: NCT05673902 Active, not recruiting - Clinical trials for Idiopathic Recurrent Pericarditis

Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Start date: December 11, 2020
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis who completed the main study CL04018068. The primary objective of the study is to evaluate the safety of RPH-104 80 mg once every 2 weeks in patients with idiopathic recurrent pericarditis who completed the main study.

NCT ID: NCT05494788 Active, not recruiting - Clinical trials for Recurrent Pericarditis

Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)

Start date: November 30, 2022
Phase: Phase 2
Study type: Interventional

Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol [CBD] solution) is known to have anti-inflammatory properties, including modulation of inflammasome signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the resolution of pericarditis symptoms, assess improvement in objective measures of disease, and during the extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRxTM.

NCT ID: NCT03231449 Active, not recruiting - Stroke Clinical Trials

A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa

FEVRIER
Start date: February 1, 2017
Phase:
Study type: Observational

FEVRIER study is an observatory of hospitalizations in cardiology units in sub-Saharan Africa.